Tharimmune, Inc. financial data

Symbol
THAR on Nasdaq
Industry
Pharmaceutical Preparations
Location
1200 Route 22 East, Bridgewater, New Jersey
State of incorporation
Delaware
Fiscal year end
December 31
Former names
Hillstream BioPharma Inc. (to 9/12/2023)
Latest financial report
10-Q - Q2 2024 - Aug 9, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 472 % +0.1%
Debt-to-equity 26.9 % -0.11%
Return On Equity -144 % +23.5%
Return On Assets -114 % +23.5%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 1.15M shares -93.4%
Common Stock, Shares, Outstanding 1.1M shares -93.5%
Entity Public Float 3.9M USD -30.4%
Common Stock, Value, Issued 111 USD -93.4%
Weighted Average Number of Shares Outstanding, Basic 962K shares +2043%
Weighted Average Number of Shares Outstanding, Diluted 962K shares +2043%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 3.51M USD -2.45%
General and Administrative Expense 5.59M USD +3.94%
Operating Income (Loss) -9.1M USD -1.38%
Nonoperating Income (Expense) 222K USD +74.8%
Net Income (Loss) Attributable to Parent -8.88M USD +0.49%
Earnings Per Share, Basic 48.2 USD/shares +95.4%
Earnings Per Share, Diluted 48.2 USD/shares +95.4%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 7.9M USD +102%
Assets, Current 8.26M USD +79.5%
Assets 8.26M USD +79.5%
Accounts Payable, Current 784K USD -31.3%
Accrued Liabilities, Current 579K USD
Liabilities, Current 1.56M USD +2.17%
Liabilities 1.56M USD +2.17%
Retained Earnings (Accumulated Deficit) -29.3M USD -43.5%
Stockholders' Equity Attributable to Parent 6.69M USD +118%
Liabilities and Equity 8.26M USD +79.5%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -2.83M USD +18.5%
Net Cash Provided by (Used in) Financing Activities 317K USD -39.4%
Common Stock, Shares Authorized 250M shares 0%
Common Stock, Shares, Issued 1.1M shares -93.5%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -2.51M USD +14.7%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 7.9M USD +102%
Deferred Tax Assets, Valuation Allowance 6.68M USD +71.2%
Deferred Tax Assets, Gross 6.68M USD +71.2%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Additional Paid in Capital 36M USD +53.1%
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense 154K USD -2.77%
Interest Expense 15.1K USD -23.4%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%